Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Venetoclax-behandling (26 cykler) med 6 cykler eller 12 cykler av epcoritamab hos patienter med återfall eller refraktär KLL eller SLL (AETHER)

30 september 2026 uppdaterad av: Stichting Hemato-Oncologie voor Volwassenen Nederland

En prospektiv randomiserad fas I/II-studie av Venetoclax-behandling (26 cykler) med 6 cykler eller 12 cykler av epcoritamab hos patienter med återfall eller refraktär kronisk lymfatisk leukemi eller litet lymfocytiskt lymfom

In this study, efficacy and safety of 2 regimens that combine the CD3-CD20 T cell engager epcoritamab with venetoclax will be tested in relapsed/refractory CLL and SLL patients. The trial starts with phase I part to establish the recommended dose level (RDL) of epcoritamab in the combination with venetoclax for the phase II trial.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

112

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

  • Australien
      • Melbourne, Australien
        • Rekrytering
        • AU-Melbourne-ALFRED
      • Melbourne, Australien
        • Rekrytering
        • AU-Melbourne-MONASH
      • Melbourne, Australien
        • Rekrytering
        • AU-Melbourne-SVHM
  • Belgien
      • Antwerp, Belgien
        • Rekrytering
        • BE-Antwerpen-ZNASTUIVENBERG
      • Roeselare, Belgien
        • Rekrytering
        • BE-Roeselare-AZDELTA
  • Danmark
      • Aalborg, Danmark
        • Indragen
        • DK-Aalborg-ALBOGUH
      • Copenhagen, Danmark
        • Rekrytering
        • DK-Copenhagen-RIGSHOSPITALET
      • Odense, Danmark
        • Rekrytering
        • DK-Odense-OUH
  • Nederländerna
      • 's-Hertogenbosch, Nederländerna
        • Rekrytering
        • NL-Den Bosch-JBZ
      • Alkmaar, Nederländerna
        • Indragen
        • NL-Alkmaar-NWZ
      • Amersfoort, Nederländerna
        • Rekrytering
        • NL-Amersfoort-MEANDERMC
      • Amsterdam, Nederländerna
        • Rekrytering
        • NL-Amsterdam-AMC
      • Dordrecht, Nederländerna
        • Rekrytering
        • NL-Dordrecht-ASZ
      • Ede, Nederländerna
        • Rekrytering
        • NL-Ede-ZGV
      • Eindhoven, Nederländerna
        • Rekrytering
        • NL-Eindhoven-CATHARINA
      • Groningen, Nederländerna
        • Rekrytering
        • NL-Groningen-UMCG
      • Leeuwarden, Nederländerna
        • Rekrytering
        • NL-Leeuwarden-MCL
      • The Hague, Nederländerna
        • Rekrytering
        • NL-Den Haag-HAGA
      • Tilburg, Nederländerna
        • Rekrytering
        • NL-Tilburg-ETZ
      • Utrecht, Nederländerna
        • Rekrytering
        • NL-Utrecht-UMCUTRECHT
  • Tyskland
      • Berlin, Tyskland
        • Indragen
        • DE-Berlin-HELIOSBERLINBUCH
      • Cologne, Tyskland
        • Rekrytering
        • DE-Köln-UKKOELN
      • Freiburg im Breisgau, Tyskland
        • Rekrytering
        • DE-Freiburg-UNIKLINIKFREIBURG
      • Greifswald, Tyskland
        • Indragen
        • DE-Greifswald-UNIGREIFSWALD
      • Halle, Tyskland
        • Rekrytering
        • DE-Halle-UMH
      • Kiel, Tyskland
        • Rekrytering
        • DE-Kiel-UKSH
      • Münster, Tyskland
        • Rekrytering
        • DE-Munster-GEMEINSCHAFTSPRAXIS
      • Stuttgart, Tyskland
        • Rekrytering
        • DE-Stuttgart-RBK
      • Ulm, Tyskland
        • Rekrytering
        • DE-Ulm-UNIKLINKULM

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Documented relapsed or refractory CLL or SLL (SLL in phase II part only) following at least one systemic 1st-line treatment

  • Requiring treatment according to IWCLL criteria (appendix A);

  • Age at least 18 years;

  • ECOG/WHO performance status 0-2;

  • In case of prior venetoclax treatment, enrollment can only occur at least 24 months after end of treatment and patients must not have progressed during venetoclax treatment;

  • Adequate BM function defined as:

    • Hemoglobin >5.6 mmol/l or Hb > 9 g/dL, unless low Hb is directly attributable to CLL infiltration of the BM, proven by BM biopsy;
    • Absolute neutrophil count (ANC) >1.0 x 109/L (1,000/μL), unless low ANC is directly attributable to CLL infiltration of the BM, proven by BM biopsy;
    • Platelet count >30 x 109/L (30,000/μL), unless low platelets is directly attributable to CLL infiltration in the BM;

  • Estimated Glomerular Filtration Rate (eGFR) (MDRD) or estimated creatinine clearance (CrCl) ≥ 50ml/min (Cockcroft-Gault appendix F);

  • Adequate liver function as indicated:

    • Serum aspartate transaminase (ASAT) and alanine transaminase (ALAT) ≤ 3.0 x upper limit of normal (ULN);
    • Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or controlled autoimmune hemolytic anemia);

  • Prothrombin time (PT)/International normal ratio (INR) <1.5x ULN and activated partial thromboplastin time (aPTT) <1.5 x ULN; unless receiving anticoagulation;

  • Negative serological testing for hepatitis B virus (HBV) (Hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (anti-HBc) negative) and hepatitis C virus (hepatitis C antibody). Patients who are positive for anti-HBc or hepatitis C antibody may be included if they have a negative PCR within 6 weeks before enrollment. Those who are PCR positive will be excluded; Please note: For patients positive for anti-HBc, HBV-DNA PCR has to be repeated every month until 12 months after last dose of study treatment.

  • Patient is able and willing to adhere to the study visit schedule and other protocol requirements;

  • Patient is capable of giving informed consent;

  • Written informed consent.

Exclusion Criteria:

  • Active CLL/SLL directed therapy within the last 14 days;

  • Prior treatment with a CD3 × CD20 bispecific antibody or CAR T-cell therapy

  • Transformation of CLL (Richter's transformation);

  • Prior allogeneic stem cell transplantation and/or solid organ transplantation;

  • Patient with a history of confirmed progressive multifocal leukoencephalopathy (PML);

  • Malignancies other than CLL currently requiring systemic therapy or not treated in curative intention or showing signs of progression after curative treatment;

  • Known allergy to xanthine oxidase inhibitors and/or rasburicase;

  • History of drug-specific hypersensitivity or anaphylaxis to any study drug (including active product or excipient components);

  • Active bleeding or uncontrolled severe bleeding diathesis (e.g., hemophilia or severe von Willebrand disease);

  • Active fungal, bacterial, and/or viral infection CTCAEgrade > 1; Please note: active controlled as well as chronic/recurrent infections are at risk of reactivation/infection during treatment;

  • Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled: infection, auto-immune hemolysis, immune thrombocytopenia, diabetes, hypertension, hyperthyroidism or hypothyroidism etc.);

  • Patient known to be HIV-positive;

  • Patient requiring treatment with a strong cytochrome P450 (CYP) 3A inhibitor/inducer (see appendix J) or anticoagulant therapy with warfarin or phenoprocoumon or other vitamin K antagonists;

  • CTCAE grade III-IV cardiovascular disease including but not limited to:

    • Unstable or uncontrolled disease/condition related to or affecting cardiac function, eg, unstable angina, congestive heart failure grade III or IV as classified by the New York Heart Association (see appendix E), uncontrolled clinically significant cardiac arrhythmia (CTCAE grade II or higher), or clinically significant electrocardiogram (ECG) abnormalities.
    • Myocardial infarction, intracranial bleed, or stroke within the past 6 months.
    • Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) >480 msec. NOTE: this criterion does not apply to subjects with a left bundle branch block.
    • Stroke or intracranial hemorrhage within 6 months prior to registration.

  • Severe pulmonary dysfunction (CTCAE grade III-IV, see appendix D);

  • Severe neurological or psychiatric disease (CTCAE grade III-IV, see appendix D);

  • Neuropathy > CTCAE grade II

  • Patient who has difficulty with or are unable to swallow oral medication, or have significant gastrointestinal disease that would limit absorption of oral medication;

  • Vaccination with live vaccines within 28 days prior to registration;

  • Use of any other experimental drug or therapy within 28 days of registration;

  • Major surgery within 28 days prior to registration;

  • Pregnant women and nursing mothers;

  • Fertile men or women of childbearing potential unless: (1) surgically sterile or ≥ 2 years after the onset of menopause; (2) willing to use a highly effective contraceptive method such as oral contraceptives, intrauterine device, sexual abstinence or combination of male condom with either cap, diaphragm, or sponge with spermicide (double barrier methods) during study treatment and for 12 months after last dose of epcoritamab and 30 days after last dose of venetoclax;

  • Previous participation in the HOVON 139 CLL or HOVON 140 CLL trial and eligible for and willing to participate in the HOVON 159 CLL trial;

  • Current participation in other clinical trial with medicinal products;

  • Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Arm A

6 cycles epcoritamab + 26 cycles venetoclax
Läkemedel: Epcoritamab

Number of cycles of epcoritamab is either 6 (cycle 1-6) or 12 (cycle 1-12). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.

Läkemedel: Venetoclax

All patients will receive venetoclax cycle 1-26 (a 5 week ramp-up of venetoclax will precede the first cycle). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
Experimentell: Arm B

12 cycles epcoritamab + 26 cycles venetoclax
Läkemedel: Epcoritamab

Number of cycles of epcoritamab is either 6 (cycle 1-6) or 12 (cycle 1-12). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.

Läkemedel: Venetoclax

All patients will receive venetoclax cycle 1-26 (a 5 week ramp-up of venetoclax will precede the first cycle). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
• Recommended phase II dose (RP2D) for the combination of venetoclax and epcoritamab based on dose limiting toxicity (DLT)
Tidsram: 6-12 months

endpoint for phase I and both arms
6-12 months
• Undetectable minimal residual disease <10-4 (uMRD) in BM in absence of progression according to IWCLL criteria at 12 weeks after cycle 26
Tidsram: 29 months

endpoint for phase II and both arms
29 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
• Minimal residual disease (MRD) status in PB at cycle 4, 6, 9, 12, 15, 18, 21, 24 and 12 weeks after cycle 26; following treatment: every 3 months for the first year, then every 6 months until relapse or until 6 years after registration
Tidsram: 6 years

both arms
6 years
• Progression free survival (PFS), defined as time from registration to the first occurrence of disease progression or death from any cause, whichever occurs first.
Tidsram: 6 years

both arms
6 years
Overall survival (OS), defined as the time from registration to death from any cause.
Tidsram: 6 years

both arms
6 years
Best overall response rate (ORR) defined as the proportion of patients with a complete response (CR), complete response with incomplete marrow recovery (CRi), or partial response (PR) according to IWCLL 2018 criteria.
Tidsram: 6 years

both arms
6 years
• Event free survival (EFS), defined as time from randomization to date start of next CLL treatment, progression or death, whichever comes first.
Tidsram: 6 years

both arms
6 years
• Time to next CLL treatment (TTNT), defined as time from randomization to next new line of treatment.
Tidsram: 6 years

both arms
6 years
• Treatment free survival (TFS), defined as time from date of last protocol treatment to date start of next (new) line of treatment, or death from any cause, whichever comes first.
Tidsram: 6 years

both arms
6 years
Duration of response (DOR), defined as time from first response (i.e., ≥PR and CR) to PD or death from any cause.
Tidsram: 6 years

both arms
6 years
• Depth (level) of minimal residual disease (MRD) measured in BM after cycle 9 and 12 weeks after cycle 26.
Tidsram: 29 months

both arms
29 months
• Depth (level) of minimal residual disease measured in PB at cycle 4, 6, 9, 12, 15, 18, 21, 24, 12 weeks after cycle 26 and thereafter every 3 months for the first year, then every 6 months until relapse or until 6 years after registration
Tidsram: 6 years

both arms
6 years
Safety parameters: Type, frequency, and severity of- adverse events (AEs) and- adverse events of special interest (AESI) and their relationship to study treatment (determined according to CTCAE v5.0).
Tidsram: 6 years

both arms
6 years
Health-related quality of life (QoL) by EORTC QLQ-C30 questionnaires.
Tidsram: 6 years

both arms
6 years
Health-related quality of life (QoL) by QLQ-CLL17 questionnaires.
Tidsram: 6 years

both arms
6 years
Health-related quality of life (QoL) by PRO-CTCAE questionnaires.
Tidsram: 6 years

both arms
6 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland

Samarbetspartners

Nordic CLL Study Group (NCLLSG)
The Australasian Leukaemia & Lymphoma Group (ALLG)
German CLL Study Group (GCLLSG)

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Användbara länkar

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 april 2024

Primärt slutförande (Beräknad)

1 mars 2029

Avslutad studie (Beräknad)

1 december 2032

Studieregistreringsdatum

Först inskickad

1 februari 2023

Först inskickad som uppfyllde QC-kriterierna

28 mars 2023

Första postat (Faktisk)

30 mars 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

30 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • HO165 CLL

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera